Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975378 | 0.92 | EGFR (1.00) | EGFRHRH3 | |
| SCHEMBL14310713 | 0.88 | EGFR (0.80) | EGFR | |
| SCHEMBL6833322 | 0.86 | EGFR (1.00) | EGFR | |
| SCHEMBL14319700 | 0.81 | EGFR (0.74) | EGFR | |
| SCHEMBL7965130 | 0.78 | EGFR (1.00) | EGFR | |
| SCHEMBL6837695 | 0.77 | EGFR (1.00) | EGFR | |
| SCHEMBL6837859 | 0.75 | EGFR (1.00) | EGFR | |
| SCHEMBL2986222 | 0.75 | EGFR (1.00) | EGFR | |
| SCHEMBL3001417 | 0.75 | EGFR (1.00) | EGFR | |
| SCHEMBL6837371 | 0.75 | EGFR (1.00) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080019907-A1 | Optical Imaging Contrast Agents | KLAVENESS JO | 2008-01-24 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019907-A1 | Optical Imaging Contrast Agents | PCSK9, APOL1, APOB | EGFR 2035/4885HRH3 3397/4885 |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | IQGAP1, AQP3, ROCK1 | EGFR 88/4885HRH3 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.